These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Sun R; Skeiky YA; Izzo A; Dheenadhayalan V; Imam Z; Penn E; Stagliano K; Haddock S; Mueller S; Fulkerson J; Scanga C; Grover A; Derrick SC; Morris S; Hone DM; Horwitz MA; Kaufmann SH; Sadoff JC Vaccine; 2009 Jul; 27(33):4412-23. PubMed ID: 19500523 [TBL] [Abstract][Full Text] [Related]
23. Comparison of the protective efficacy of bacille calmette-Guérin vaccination against aerosol challenge with Mycobacterium tuberculosis and Mycobacterium bovis. Williams A; Davies A; Marsh PD; Chambers MA; Hewinson RG Clin Infect Dis; 2000 Jun; 30 Suppl 3():S299-301. PubMed ID: 10875804 [TBL] [Abstract][Full Text] [Related]
24. Anti-mycobacterial activity correlates with altered DNA methylation pattern in immune cells from BCG-vaccinated subjects. Verma D; Parasa VR; Raffetseder J; Martis M; Mehta RB; Netea M; Lerm M Sci Rep; 2017 Sep; 7(1):12305. PubMed ID: 28951586 [TBL] [Abstract][Full Text] [Related]
25. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Elias D; Akuffo H; Britton S Trans R Soc Trop Med Hyg; 2005 May; 99(5):363-8. PubMed ID: 15780343 [TBL] [Abstract][Full Text] [Related]
26. Current perspective in tuberculosis vaccine development for high TB endemic regions. Husain AA; Daginawala HF; Singh L; Kashyap RS Tuberculosis (Edinb); 2016 May; 98():149-58. PubMed ID: 27156631 [TBL] [Abstract][Full Text] [Related]
27. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Waeckerle-Men Y; Bruffaerts N; Liang Y; Jurion F; Sander P; Kündig TM; Huygen K; Johansen P Vaccine; 2013 Feb; 31(7):1057-64. PubMed ID: 23273509 [TBL] [Abstract][Full Text] [Related]
28. AdHu5Ag85A Respiratory Mucosal Boost Immunization Enhances Protection against Pulmonary Tuberculosis in BCG-Primed Non-Human Primates. Jeyanathan M; Shao Z; Yu X; Harkness R; Jiang R; Li J; Xing Z; Zhu T PLoS One; 2015; 10(8):e0135009. PubMed ID: 26252520 [TBL] [Abstract][Full Text] [Related]
29. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy. Lu M; Xia ZY; Bao L Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251 [TBL] [Abstract][Full Text] [Related]
30. A Perspective on the Success and Failure of BCG. Kumar P Front Immunol; 2021; 12():778028. PubMed ID: 34970263 [TBL] [Abstract][Full Text] [Related]
31. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Black GF; Weir RE; Floyd S; Bliss L; Warndorff DK; Crampin AC; Ngwira B; Sichali L; Nazareth B; Blackwell JM; Branson K; Chaguluka SD; Donovan L; Jarman E; King E; Fine PE; Dockrell HM Lancet; 2002 Apr; 359(9315):1393-401. PubMed ID: 11978337 [TBL] [Abstract][Full Text] [Related]
33. Monocyte response receptors in BCG driven delayed type hypersensitivity to tuberculin. Strapagiel D; Kasztalska K; Druszczyńska M; Kowalewicz-Kulbat M; Vrba A; Matusiak A; Chmiela M; Rudnicka W Folia Histochem Cytobiol; 2008; 46(3):353-9. PubMed ID: 19056540 [TBL] [Abstract][Full Text] [Related]
34. Repeated Aerosolized-Boosting with Gamma-Irradiated Mycobacterium bovis BCG Confers Improved Pulmonary Protection against the Hypervirulent Mycobacterium tuberculosis Strain HN878 in Mice. Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Eum SY; Cho SN; Shin SJ PLoS One; 2015; 10(10):e0141577. PubMed ID: 26509812 [TBL] [Abstract][Full Text] [Related]
35. Recombinant BCG prime and PPE protein boost provides potent protection against acute Mycobacterium tuberculosis infection in mice. Yang E; Gu J; Wang F; Wang H; Shen H; Chen ZW Microb Pathog; 2016 Apr; 93():1-7. PubMed ID: 26792673 [TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and protective efficacy of heterologous prime-boost regimens with mycobacterial vaccines and recombinant adenovirus- and poxvirus-vectored vaccines against murine tuberculosis. You Q; Wu Y; Wu Y; Wei W; Wang C; Jiang D; Yu X; Zhang X; Wang Y; Tang Z; Jiang C; Kong W Int J Infect Dis; 2012 Nov; 16(11):e816-25. PubMed ID: 22921259 [TBL] [Abstract][Full Text] [Related]
37. Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice. Zhang H; Peng P; Miao S; Zhao Y; Mao F; Wang L; Bai Y; Xu Z; Wei S; Shi C Scand J Immunol; 2010 Oct; 72(4):349-57. PubMed ID: 20883320 [TBL] [Abstract][Full Text] [Related]
38. The Ag85B protein of the BCG vaccine facilitates macrophage uptake but is dispensable for protection against aerosol Mycobacterium tuberculosis infection. Prendergast KA; Counoupas C; Leotta L; Eto C; Bitter W; Winter N; Triccas JA Vaccine; 2016 May; 34(23):2608-15. PubMed ID: 27060378 [TBL] [Abstract][Full Text] [Related]
39. Ipr1 modified BCG as a novel vaccine induces stronger immunity than BCG against tuberculosis infection in mice. Wang Y; Yang C; He Y; Zhan X; Xu L Mol Med Rep; 2016 Aug; 14(2):1756-64. PubMed ID: 27356552 [TBL] [Abstract][Full Text] [Related]
40. A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development. Pepponi I; Khatri B; Tanner R; Villarreal-Ramos B; Vordermeier M; McShane H Tuberculosis (Edinb); 2017 Sep; 106():118-122. PubMed ID: 28802398 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]